Skip Navigation

Annals of Oncology 2007 18(9):1429-1430; doi:10.1093/annonc/mdm415
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Brown, R
Right arrow Articles by Glasspool, R
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Brown, R
Right arrow Articles by Glasspool, R
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2007 European Society for Medical Oncology

editorials

Epigenetic modulation of resistance to chemotherapy?

R Brown1,* and R Glasspool2

1 Department of Oncology, Imperial College, London
2 Beatson West of Scotland Cancer Centre, Glasgow, UK

* (E-mail: r.brown@beatson.gla.ac.uk)

The first 10% of the full text of this article appears below.

Drug sensitivity is influenced by alterations in gene expression [1]. Gene expression patterns in tumours are determined by both genetic and epigenetic changes [2]. Epigenetic changes are stable and heritable changes in gene expression resulting from modifications of DNA and associated proteins that do not involve an alteration in DNA sequence. Epigenetic modification occurs both during tumour development and during the acquisition of drug resistance and leads to altered expression of many hundreds of genes [3]. Unlike genetic changes, epigenetic modifications require active maintenance so they can be manipulated by small molecules and provide a potential therapeutic target [4]. Two common epigenetic changes are CpG island methylation and histone acetylation, both of which can be modulated using DNA methyltransferase (DNMT) and histone deacetylase (HDAC) inhibitors, respectively. DNMT inhibitors are . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?